

December 15, 2022

# Medical drug frequency review update

## New post-service claim review for UnitedHealthcare® Medicare Advantage Plans

**Effective March 1, 2023**, we will conduct post-service medical claims reviews of certain drugs to ensure adherence to Food and Drug Administration (FDA)-approved [prescribing guidelines](#). We will deny claims for these drugs that are billed at a frequency that exceeds the dosing guidelines, unless there is an authorization on file indicating an approval of the more frequent dosing. Our review will typically occur 2-10 days after the claim submission.

If we deny a claim because it doesn't meet the FDA prescribing guidelines, the provider is responsible for the resulting costs.

### Drugs included in this policy

The drugs and CPT® codes that are included in this post-service review are:

- Denosumab (J0897)
- Entyvio (J3380)
- Infliximab (J1745, Q5103, Q5104)
- Botox (J0585)

The [Medicare Advantage Medications/Drugs \(Outpatient/Part B\) Coverage Summary](#) references these drugs and the drug policy used as the basis for the dosage and frequency review. Analysis has shown that these drugs are being administered at a frequency that exceeds the FDA prescribing guidelines as outlined in the drug policy.

### Questions?

For more information or answers to specific questions, call the Provider Services phone number on the back of the member ID card.

CPT® is a registered trademark of the American Medical Association.

PCA-22-03926-Optum-News\_11302022



Discover



Get





**more news**



**personalized  
news**